Summary of guidance relevant to general practice in October 2011
Ticagrelor for the treatment of acute coronary syndromes (ACS)
This final guidance recommends that GPs can prescribe ticagrelor (Brilique), in combination with low-dose aspirin for up to 12 months, for patients with acute coronary syndromes (ACS).
Ticagrelor is an anti-platelet drug which works by reducing or preventing the formation of blood clots.
It is licensed for the treatment of people with ACS who are managed medically or who are having a procedure called a percutaneous coronary intervention to widen narrowed arteries in the heart.
NICE recommends that the drug be used, in combination with aspirin, as a treatment option in people with STEMI who are to undergo primary percutaneous coronary intervention (PCI) and in people with NSTEMI.
It is also recommended as a treatment option for people with unstable angina, which is defined as changes on electrocardiogram suggestive of ischaemia plus one characteristic associated with cardiovascular disease.
Patients admitted to hospital with unstable angina could also benefit from ticagrelor, says NICE.
Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist.
Support tools to help you put this guidance into practice
NICE has produced a clinical audit tool tool to help put this recommendation into practice.
26 Ocotber 2011